Brief: Janux Therapeutics Announces First Participant Dosed In Phase 1 Study Of Janx014
16/04/2026 21:44
April 16 (Reuters) - Janux Therapeutics Inc JANX.O: JANUX THERAPEUTICS ANNOUNCES FIRST PARTICIPANT DOSED IN PHASE 1 STUDY OF JANX014 Source text: ID:nBw14QlGRa Further company coverage: JANX.O ((Reuters.Briefs@thomsonreuters.com;))